Cargando…

Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview

BACKGROUND: Although several studies have assessed the safety, efficacy, and effectiveness of interventions in treating the COVID-19, many of them have limitations that can have an immense impact on their results. This study aims to assess the potential limitations in systematic reviews (SRs) that e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohseni, Mahsa, Ameri, Hosein, Arab-Zozani, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531544/
https://www.ncbi.nlm.nih.gov/pubmed/36203750
http://dx.doi.org/10.3389/fmed.2022.966632
_version_ 1784801924139188224
author Mohseni, Mahsa
Ameri, Hosein
Arab-Zozani, Morteza
author_facet Mohseni, Mahsa
Ameri, Hosein
Arab-Zozani, Morteza
author_sort Mohseni, Mahsa
collection PubMed
description BACKGROUND: Although several studies have assessed the safety, efficacy, and effectiveness of interventions in treating the COVID-19, many of them have limitations that can have an immense impact on their results. This study aims to assess the potential limitations in systematic reviews (SRs) that evaluate the effect of interventions on the treatment of the COVID-19. METHODS: PubMed, Scopus, and Web of Sciences (WOS) databases were searched from inception to January 1, 2022. All systematic reviews investigated the effectiveness, efficacy, safety, and outcome of the main intervention (Favipiravir, Remdesivir, Hydroxychloroquine, Ivermectin, Lopinavir/Ritonavir, or Tocilizumab) for the treatment of COVID-19 patients and reported the potential limitations of the included studies. We assessed the quality of the included studies using the Quality Assessment Tool (QAT) for review articles. We conducted a content analysis and prepared a narrative summary of the limitations. RESULTS: Forty-six studies were included in this review. Ninety one percent of the included studies scored as strong quality and the remaining (9%) as moderate quality. Only 29.7% of the included systematic reviews have a registered protocol. 26% of the included studies mentioned a funding statement. The main limitations of the included studies were categorized in 10 domains: sample size, heterogeneity, follow-up, treatment, including studies, design, definitions, synthesis, quality, and search. CONCLUSION: Various limitations have been reported in all the included studies. Indeed, the existence of limitations in studies can affect their results, therefore, identifying these limitations can help researchers design better studies. As a result, stronger studies with more reliable results will be reported and disseminated. Further research on COVID-19 SRs is essential to improve research quality and also, efficiency among scientists across the world.
format Online
Article
Text
id pubmed-9531544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95315442022-10-05 Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview Mohseni, Mahsa Ameri, Hosein Arab-Zozani, Morteza Front Med (Lausanne) Medicine BACKGROUND: Although several studies have assessed the safety, efficacy, and effectiveness of interventions in treating the COVID-19, many of them have limitations that can have an immense impact on their results. This study aims to assess the potential limitations in systematic reviews (SRs) that evaluate the effect of interventions on the treatment of the COVID-19. METHODS: PubMed, Scopus, and Web of Sciences (WOS) databases were searched from inception to January 1, 2022. All systematic reviews investigated the effectiveness, efficacy, safety, and outcome of the main intervention (Favipiravir, Remdesivir, Hydroxychloroquine, Ivermectin, Lopinavir/Ritonavir, or Tocilizumab) for the treatment of COVID-19 patients and reported the potential limitations of the included studies. We assessed the quality of the included studies using the Quality Assessment Tool (QAT) for review articles. We conducted a content analysis and prepared a narrative summary of the limitations. RESULTS: Forty-six studies were included in this review. Ninety one percent of the included studies scored as strong quality and the remaining (9%) as moderate quality. Only 29.7% of the included systematic reviews have a registered protocol. 26% of the included studies mentioned a funding statement. The main limitations of the included studies were categorized in 10 domains: sample size, heterogeneity, follow-up, treatment, including studies, design, definitions, synthesis, quality, and search. CONCLUSION: Various limitations have been reported in all the included studies. Indeed, the existence of limitations in studies can affect their results, therefore, identifying these limitations can help researchers design better studies. As a result, stronger studies with more reliable results will be reported and disseminated. Further research on COVID-19 SRs is essential to improve research quality and also, efficiency among scientists across the world. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9531544/ /pubmed/36203750 http://dx.doi.org/10.3389/fmed.2022.966632 Text en Copyright © 2022 Mohseni, Ameri and Arab-Zozani. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Mohseni, Mahsa
Ameri, Hosein
Arab-Zozani, Morteza
Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title_full Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title_fullStr Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title_full_unstemmed Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title_short Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
title_sort potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of covid-19 patients: an overview
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531544/
https://www.ncbi.nlm.nih.gov/pubmed/36203750
http://dx.doi.org/10.3389/fmed.2022.966632
work_keys_str_mv AT mohsenimahsa potentiallimitationsinsystematicreviewstudiesassessingtheeffectofthemaininterventionfortreatmenttherapyofcovid19patientsanoverview
AT amerihosein potentiallimitationsinsystematicreviewstudiesassessingtheeffectofthemaininterventionfortreatmenttherapyofcovid19patientsanoverview
AT arabzozanimorteza potentiallimitationsinsystematicreviewstudiesassessingtheeffectofthemaininterventionfortreatmenttherapyofcovid19patientsanoverview